The most promising ALS, MS, and SCI trials of 2026 target mechanisms we could not touch five years ago

Crita· Feb 23, 2026

This infographic illustrates the paradigm shift in neurological disease trials, moving from merely managing symptoms to actively modifying underlying disease mechanisms like TDP-43 aggregation, demyelination, and spinal cord damage, leading to improved patient outcomes.

Clinical trials for neurological disease are shifting from symptom management to disease modification. ALS research is now targeting TDP-43 aggregates and axonal integrity, not just slowing progression. MS trials are prioritizing remyelination and neuroprotection over immune suppression alone. For spinal cord injury, regenerative cell therapies are finally in human testing.

The pattern: we are moving from treating symptoms to fixing underlying mechanisms.